Fast Acting Virus Control Strategies for Production Animal Diseases

Información del proyecto

FACTs

Identificador del acuerdo de subvención: 672586

DOI

10.3030/672586

Proyecto cerrado

Fecha de la firma de la CE 8 Abril 2015

Fecha de inicio 1 Mayo 2015

Fecha de finalización 31 Octubre 2015

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

ARATANA THERAPEUTICS NV
Belgium

Periodic Reporting for period 1 - FACTs (Fast Acting Virus Control Strategies for Production Animal Diseases)

Período documentado: 2015-05-01 hasta 2015-10-31

Resumen del contexto y de los objetivos generales del proyecto

ViroVet was the operating name of Aratana Therapeutics’ livestock team. The strategic business plan that resulted from FACTs led to ViroVet’s incorporation as a dedicated, disruptive biotech company (30 July 2015). ViroVet will focus on the introduction of a product for bovine viral diarrhoea (BVD) and of a combination vaccine for small ruminants; both TLR-6 products. Generated sales will support double-digit growth of ViroVet; revenue that will be used for pipeline expansion.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The market opportunity of the BVD product was confirmed, inflection points were determined for BVD control in the beef cattle chain, and regulatory requirements and development timelines were established, supporting EU and US product launch. The envisioned business idea proved technologically and practically viable. ViroVet’s ambition to introduce the BVD product as a new standard of care in the beef industry was consolidated by economic analysis.
Investigations into unmet needs of the livestock industry resulted in the addition of 6 new product candidates to ViroVet’s portfolio, ensuring a healthy pipeline.
The refined business plan was the basis of ViroVet’s incorporation on July 30th, 2015 as a separate legal entity. ViroVet management is now in advanced discussions with potential lead and co-lead investors with the aim to close a series A round in early 2016.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

ViroVet will deliver innovative solutions to be used alone or in combination with existing products and measures providing livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.
ViroVet’s livestock solutions will create a healthy company that aids in battling some societal issues of our time:
• Global human population growth drives animal-based protein needs. Reducing the burden of viral disease will provide healthier livestock and better performing production systems.
• Antibiotic use will be decreased as ViroVet’s technologies will better protect livestock from viral disease and associated bacterial infections, reducing the risk for antimicrobial resistance through overuse/misuse in veterinary practice.
• Some of ViroVet’s products are aimed at controlling infectious diseases at source (e.g. by addressing African/Asian markets) thereby reducing the risk of spread as a result of climate change.
ViroVet intends to apply for an SME Instrument Phase 2 to support full introduction of the BVD product.

logo-virovet-landscape-small.jpg